Shanghai Junshi Bioscience Co., Ltd.
Clinical trials sponsored by Shanghai Junshi Bioscience Co., Ltd., explained in plain language.
-
New cancer drug combo trial opens for patients Who've run out of options
Disease control Not yet recruitingThis study is testing several new cancer drugs, JS212 and JS213, to see if they are safe and can help control advanced solid tumors. It will test the drugs alone and in different combinations. The trial is for adults with specific advanced cancers (like kidney, prostate, bladder,…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New drug cocktail targets tough lung cancers in major trial
Disease control Not yet recruitingThis study is testing whether combining a new drug called JS212 with other cancer medications can help control advanced lung cancer. Researchers will enroll about 864 patients whose cancer has progressed despite standard treatments or who haven't yet received systemic therapy. Th…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo trial offers hope for Tough-to-Treat esophageal cancer
Disease control Not yet recruitingThis study aims to test the safety and early effectiveness of a new combination therapy called JS212 for adults with advanced esophageal cancer that has spread or returned. It will involve about 280 patients who have not received prior drug treatment for their advanced disease. T…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC